Nature Medicine

At #ESMO26: in the phase 2 MDT-BRIDGE trial, neoadjuvant durvalumab + chemotherapy in patients with resectable NSCLC, followed by multidisciplinary reassessment, enabled surgery in the majority of patients, leading to encouraging response rates

At #ESMO26: In an analysis of the phase 3 RELATIVITY-047 trial comparing relatlimab + nivolumab vs nivolumab alone in patients with melanoma, high baseline levels of LAG3hi CD8+ T cells were associated with improved response in the combination arm

At #ESMO26: In a phase 2a trial, treatment of patients with immune checkpoint-inhibitor-naive bladder cancer with the GDF15-neutralizing antibody visugromab + nivolumab produced encouraging pathological complete response with no new safety signals.

CAR-T therapies are generating excitement beyond cancer, with trials in autoimmune disease. But recent results have complicated that picture. In our latest news story, Marianne Guenot asks what the latest developments mean for the field. Read more:

A high-profile chronotherapy trial was retracted. What does the fallout mean for a field built around the idea that when we treat disease can matter? Natalie Healey investigates what comes next for chronotherapy in NatureMedicine. Read more:

News & Views: New studies of trends in the global burden of #measles and #pertussis offer a reminder of how much vaccination has achieved, and a warning of the need for more resilient and sustainable vaccination programs.

Now #ESMO26: In a phase 2 trial evaluating a peptide vaccine in patients with mKRAS PDAC, the 1ry endpoint of DFS was not met but prespecified analyses showed that significant DFS was seen in the vaccine arm in patients with ctDNA- disease.

As presented at #ESMO26: In a phase 1/2 trial in patients with solid tumors, a first-in-class bispecific antibody targeting the Vβ6/Vβ10 T cell subsets was well tolerated and showed preliminary efficacy signals in immunologically hot and cold tumors

News & Views: A small study shows that patients with #epilepsy can help fine-tune their own seizure detectors by chatting with an #AI agent. However, the more difficult challenge ahead is to build AI that responds appropriately.

The liver can warn us of metabolic dysfunction long before serious disease develops. So why do we wait until people are “sick enough” to act? Jeffrey V. Lazarus argues for earlier action in a new World View. Read the article:

News & Views: A secondary analysis of trial data shows that both host antibodies and infused antibodies against #HIV help to delay viral rebound after interruption of therapy, which could inform approaches to durable, ART-free HIV control.

News & Views: A new study tackles issues around operational and decisional trust of #agenticAI, using locally deployed, on-premise agents and referral of uncertain cases — but what happens after referral remains untested.

Happening today, free to join...

In a randomised phase 2 trial, patients with metastatic hormone sensitive prostate cancer treated with PARP inhibitor talazoparib combined with androgen receptor inhibitor enzalutamide had an improved PSA response vs enzalutamide alone.

A small epilepsy monitoring study shows that a moderated, LLM-based chat interface lets patients converse with their EEG monitoring in real time using a smartphone and patient feedback cut seizure-detector false alarms by 80% without clinician input

Utilizing longitudinal data from 52,236 patients with cancer, this study created a multimodal atlas of cancer cachexia, demonstrating that weight-loss episodes are linked to systemic serologic signatures and specific tumor genotypes.

A phase 1 trial shows that treatment of patients with high-grade serous ovarian cancer with personalized neoantigen vaccines combined with PD-1 blockade was feasible and led to tumor-specific immune responses in many patients. http://dlvr.it/TVwzPT @DFCI_NeoVax

📢Webinar: Join Nature Medicine & Nature Reviews Nephrology for a discussion on approaches to financing #dialysis, a leading cause of catastrophic health expenditure Wednesday, Oct 21 With Valerie Luyckx, Ole Norheim, Laura Sola, Yot Teerawattananon @natrevneph.nature.com cassyni.com/events/5PxZX...

A cross sectional analysis on lab data from 2 independent cohorts reveals that the final menstrual period marks an abrupt, multisystem physiological shift, occurring 10 years before menopause onset. @urialonlab.bsky.social

An analysis of code availability in the open access published literature shows that code sharing in clinical prediction models remains limited, and reveals significant variability in practices and documentation quality.

Applied to samples from more than 600 patients and controls, urinary cell-free RNA profiling with uRARE-seq demonstrated high sensitivity in detecting bladder cancer, and correlated with treatment response

Global age and sex-specific reference curves for 11 pain sites, from 6.1 million people in 118 countries, found higher late-life pain in the lowest HDI countries, and provide a tool for benchmarking pain assessments in other cohorts.

A pragmatic cluster-randomised trial done in Yobe State, Northern Nigeria found that distributing small-quantity lipid-based nutrient supplements alongside routine immunization services substantially increased measles vaccination uptake in children.

MedGemma, a collection of medical vision–language foundation models based on Gemma 3, demonstrates advanced medical understanding and reasoning on images and text across multiple medical imaging domains

New studies provide evidence on performance, safety & implementation of the #Galleri multi-cancer early detection test, underscoring the next challenge: demonstrating population-level benefit. Catherine Marinac et al. @DanaFarber discuss the data:

News & Views: Inhibition of the Werner syndrome helicase enzyme exploits a new synthetic lethal vulnerability in cancers with microsatellite instability, offering a new way to target these tumors. @JiaJennyLiu discusses the data.

#Reproducibility is crucial for trustworthy science, but reproducible research practices are inconsistently used. Judy Zhong & colleagues review the current landscape and highlight persistent barriers and responses.

Redesigning cardiovascular medicine around sex differences: Hester den Ruijter & colleagues connect evidence across mechanistic and clinical domains, focusing on female-predominant cardiovascular conditions such as #SCAD, #Takotsubo syndrome etc.

Integrating numerous multimodal, patient-level biomarkers enhances the prediction of #cancer #immunotherapy response, but generalizability is still a challenge. News & Views from Raquel Perez-Lopez, Mireia Crispin-Ortuzar @CRUKCamCentre @VHIO

Trials of selective #KRASG12D inhibitors show promise in advanced cancers with G12D mutations, signaling a shift in the treatment landscape — and potential across tumor types and disease stages. News & Views from Jennifer Knox et al @PMResearch_UHN

An in-depth phenomic analysis of health and disease patterns from 1.9 million participants of the Our Future Health cohort reports the prevalence of health conditions and medication-use patterns compared to national UK estimates and the UK Biobank.

New studies provide evidence on performance, safety & implementation of the #Galleri multi-cancer early detection test, underscoring the next challenge: demonstrating population-level benefit. Catherine Marinac et al. @DanaFarber discuss the data:

A 15-year cohort study shows that #Alzheimers #dementia risk is jointly shaped by Alzheimer’s pathology and #CognitiveResilience, with high #resilience linked to lower risk even under greater pathology.

Integrating numerous multimodal, patient-level biomarkers enhances the prediction of #cancer #immunotherapy response, but generalizability is still a challenge. News & Views from Raquel Perez-Lopez, Mireia Crispin-Ortuzar @CRUKCamCentre @VHIO

Trials of selective #KRASG12D inhibitors show promise in advanced cancers with G12D mutations, signaling a shift in the treatment landscape — and potential across tumor types and disease stages. News & Views from Jennifer Knox et al @PMResearch_UHN

⚡ Our September issue is live! Featuring new research on #epigenetic clocks, #measles transmission, #preeclampsia, #AI for retinal disease diagnosis, #iPSCs for heart failure and much more including Reviews, News and Opinion. Read it here:

New article today: EBV reactivation priming of the peripheral immune system in multiple sclerosis relapse Read more via link:

An in-depth phenomic analysis of health and disease patterns from 1.9 million participants of the Our Future Health cohort reports the prevalence of health conditions and medication-use patterns compared to national UK estimates and the UK Biobank.

A 15-year cohort study shows that #Alzheimers #dementia risk is jointly shaped by Alzheimer’s pathology and #CognitiveResilience, with high #resilience linked to lower risk even under greater pathology.

New article today: Rethinking the global health system for a new international order Read more via link:

Rethinking the global health system for a new international order

News & Views: An early assessment of the UK’s 'Our Future Health' project shows how national-scale cohorts might reshape population medicine by accelerating discovery and clinical recruitment – but only if biases are carefully measured and managed.

As policymakers debate whether AI "superintelligence" should be banned, what would medical superintelligence actually look like? In Nature Medicine, Ethan Goh and colleagues propose a framework to test it.

What happens when an AI agent is deployed in routine clinical care? In a new Comment, Tien Yin Wong and colleagues share early lessons from the real-world deployment of an AI-native model in a large public hospital in Beijing, China.

As clinical trial activity grows across Africa, strengthening ethics review and regulatory oversight is becoming increasingly important. A new Nature Medicine Correspondence shares lessons from the TRACE initiative. Read more:

Obesity medicines are reshaping healthcare faster than many systems are prepared for. In a new Nature Medicine World View, Naveed Sattar @UofGlasgow argues that health systems must adapt to a new era of obesity treatment. Read more:

Japan has introduced a legally binding ban on heritable human genome editing. In a new Nature Medicine Correspondence, Tsutomu Sawai examines what the legislation achieves, and where its limits remain. Read more:

A new class of medicines is coming of age. The approval of the first PROTAC for breast cancer demonstrated that drugs can be designed to bring proteins together, opening new opportunities to target disease. Read more:

#ESCCongress 2026: Combining direct oral anticoagulants with powerful P2Y12 inhibitors in atrial fibrillation and acute coronary syndrome patients shows higher bleeding risk without lower ischemic events, compared to using clopidogrel and aspirin.

As presented at the 2026 #ESCCongress: A secondary analysis of the CARDIOTTRansform trial revealed that eplontersen benefited patients with transthyretin amyloid cardiomyopathy who were not on stabilizers, but not those who were.